Clinical studies recruiting near Shantou

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carbop
Phase 3 · Tumor Hospital of the affiliated medical college of Shantou · Hoffmann-La Roche · NCT06793215 Effect of Different Concentrations of Sevoflurane for Anesthesia Induction in Pediatric Ophthalmic Surgery
NA · Joint Shantou International Eye Center of Shantou University · Joint Shantou International Eye Center of Shantou University · NCT07450495 A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
Phase 2 · Research Site · AstraZeneca · NCT07276581 Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS
Phase 3 · Cancer Hospital of Shantou University Medical College · Eli Lilly and Company · NCT06890598 A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
Phase 1/Phase 2 · Cancer Hospital of Shantou University Medical College · Advenchen Laboratories, LLC · NCT07392736 Serum and Tissue Metabolite-based Prediction of Sentinel Lymph Node Metastasis in Breast Cancer
Phase N/A · Shantou Central Hospital · Shantou Central Hospital · NCT06001528 Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer
Phase 1/Phase 2 · The First Affiliated Hospital of Shantou University Medical · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT07367516 Aortic Valve Diseases RISk facTOr assessmenT and Prognosis modeL Construction
Phase N/A · Second Affiliated Hospital of Shantou University Medical Col · Sun Yat-sen University · NCT06069232 A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent
Phase 3 · Shantou Central Hospital · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT07003074 EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Phase 3 · Shantou Central Hospital · Boehringer Ingelheim · NCT06531824 Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Phase 3 · Cancer Hospital of Shantou University Medical College · Sun Yat-sen University · NCT06239727 The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management
NA · Research Site · AstraZeneca · NCT06909773 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
Phase 3 · Cancer Hospital of Shantou University Medical College · Ming-Yuan Chen · NCT07328854 A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel
Phase 3 · Cancer Hospital of Shantou University Medical College /ID# 2 · AbbVie · NCT04928846 Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemo
Phase 3 · Shantou University Medical College Affiliated Tumor Hospital · Shanghai Chia Tai Tianqing Pharmaceutical Technology Develop · NCT07385703 A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Phase 3 · The Second Affiliated Hospital of Shantou University School · Pfizer · NCT06629779 To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patt
Phase N/A · The First Affiliated Hospital of Shantou University Medical · Ferring Pharmaceuticals · NCT07029451 Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-posit
Phase N/A · Cancer Hospital of Shantou University Medical College · Daiichi Sankyo · NCT06846996 BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
Phase 3 · Cancer Hospital of Shantou University Medical College · BeOne Medicines · NCT07492641 Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinom
Phase 3 · Cancer Hospital of Shantou University Medical College · Ming-Yuan Chen · NCT07328841 An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase 3 · Research Site · AstraZeneca · NCT05952557 Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
NA · Cancer Hospital of Shantou University Medical College · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT07095023 A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esopha
Phase 3 · 169 · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT07487896 Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
Phase 3 · Joint Shantou International Eye Center, Shantou University a · Innostellar Biotherapeutics Co.,Ltd · NCT07317934 Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIR
Phase 3 · Novartis Investigative Site · Novartis Pharmaceuticals · NCT06133972 Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.
Phase 3 · Affiliated Cancer Hospital of Shantou University Medical Col · Sun Yat-sen University · NCT07201337 Efficacy and Safety of SR1375 in Adult Patients With CAP
Phase 2 · The First Affiliated Hospital of Shantou University Medical · Shanghai SIMR Biotechnology Co., Ltd. · NCT06577558 Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema
Phase 3 · Shantou University-The Chinese University of Hong Kong Joint · Bio-Thera Solutions · NCT07515079 Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal
Phase 2 · Cancer Hospital, Shantou University Medical College · Chuangzhen Chen · NCT07339488 Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe At
Phase 2 · Novartis Investigative Site · Novartis Pharmaceuticals · NCT06947993

Look up another city

Look up another condition